作者
María J Pérez‐Sáez, Miquel Blasco, Dolores Redondo‐Pachón, Pedro Ventura‐Aguiar, Teresa Bada‐Bosch, Isabel Pérez‐Flores, Edoardo Melilli, Luis A Sánchez‐Cámara, María O López‐Oliva, Cristina Canal, Amir Shabaka, Núria Garra‐Moncau, Paloma L Martín‐Moreno, Verónica López, Román Hernández‐Gallego, Orlando Siverio, Cristina Galeano, Jordi Espí‐Reig, Carlos J Cabezas, María T Rodrigo, Laura Llinàs‐Mallol, María J Fernández‐Reyes, Leónidas Cruzado‐Vega, Lourdes Pérez‐Tamajón, Raquel Santana‐Estupiñán, María C Ruiz‐Fuentes, Guadalupe Tabernero, Sofía Zárraga, Juan C Ruiz, Alex Gutiérrez‐Dalmau, Auxiliadora Mazuecos, Emilio Sánchez‐Álvarez, Marta Crespo, Julio Pascual, Spanish Society of Nephrology COVID‐19 Group
发表日期
2020/11
期刊
American Journal of Transplantation
卷号
20
期号
11
页码范围
3182-3190
简介
Acute respiratory distress syndrome associated with coronavirus infection is related to a cytokine storm with large interleukin‐6 (IL‐6) release. The IL‐6‐receptor blocker tocilizumab may control the aberrant host immune response in patients with coronavirus disease 2019 (COVID‐19) . In this pandemic, kidney transplant (KT) recipients are a high‐risk population for severe infection and showed poor outcomes. We present a multicenter cohort study of 80 KT patients with severe COVID‐19 treated with tocilizumab during hospital admission. High mortality rate was identified (32.5%), related with older age (hazard ratio [HR] 3.12 for those older than 60 years, P = .039). IL‐6 and other inflammatory markers, including lactic acid dehydrogenase, ferritin, and D‐dimer increased early after tocilizumab administration and their values were higher in nonsurvivors. Instead, C‐reactive protein (CRP) levels decreased after …
学术搜索中的文章
MJ Pérez‐Sáez, M Blasco, D Redondo‐Pachón… - American Journal of Transplantation, 2020